Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gallbladder: A Systematic Review of Outcomes Following Surgical Management.
Gallbladder
MANEC
adenoneuroendocrine
carcinoma
mixed
review
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
20
07
2019
revised:
04
08
2019
accepted:
05
08
2019
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
20
3
2020
Statut:
ppublish
Résumé
Mixed adenoneuroendocrine carcinomas (MANEC) are uncommon tumors exhibiting both adenocarcinomatous and neuroendocrine differentiation. They most commonly arise in the colon, appendix, rectum or stomach, however, a limited number of MANECs have been reported to originate in the gallbladder (gMANEC). The aim of our systematic review was to accumulate the existing data on gMANEC with special attention to the clinicopathological characteristics, surgical approach, recurrence and survival rates of patients diagnosed with this rare malignancy. A comprehensive search of the literature was undertaken. A total of 15 studies (14 case reports and 1 case series), which comprised 19 patients who successfully underwent surgical treatment for gMANEC were included in our systematic review. During a median follow-up of 8 months (range=2-48 months) the overall survival was 87% and the recurrence rate was 21%. Achievement of complete surgical resection is the mainstay of the therapeutic management. Additionally, the stage of the disease and the histopathological mapping of these tumors affect decision-making for adjuvant chemotherapy and seem to define the prognostic course of each patient.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Mixed adenoneuroendocrine carcinomas (MANEC) are uncommon tumors exhibiting both adenocarcinomatous and neuroendocrine differentiation. They most commonly arise in the colon, appendix, rectum or stomach, however, a limited number of MANECs have been reported to originate in the gallbladder (gMANEC). The aim of our systematic review was to accumulate the existing data on gMANEC with special attention to the clinicopathological characteristics, surgical approach, recurrence and survival rates of patients diagnosed with this rare malignancy.
MATERIALS AND METHODS
METHODS
A comprehensive search of the literature was undertaken.
RESULTS
RESULTS
A total of 15 studies (14 case reports and 1 case series), which comprised 19 patients who successfully underwent surgical treatment for gMANEC were included in our systematic review. During a median follow-up of 8 months (range=2-48 months) the overall survival was 87% and the recurrence rate was 21%.
CONCLUSION
CONCLUSIONS
Achievement of complete surgical resection is the mainstay of the therapeutic management. Additionally, the stage of the disease and the histopathological mapping of these tumors affect decision-making for adjuvant chemotherapy and seem to define the prognostic course of each patient.
Identifiants
pubmed: 31662496
pii: 33/6/1721
doi: 10.21873/invivo.11662
pmc: PMC6899129
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1721-1726Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Balkan Med J. 2018 Mar 19;35(3):263-267
pubmed: 29551754
World J Gastroenterol. 2014 Sep 7;20(33):11916-20
pubmed: 25206300
Front Oncol. 2016 Jun 13;6:148
pubmed: 27379210
Mol Clin Oncol. 2018 Aug;9(2):219-222
pubmed: 30101026
Clin J Gastroenterol. 2018 Aug;11(4):320-326
pubmed: 29442219
Pathol Int. 2013 Feb;63(2):113-9
pubmed: 23464969
Perm J. 2019;23:
pubmed: 30939279
Pathol Int. 2014 Sep;64(9):465-71
pubmed: 25146100
Histol Histopathol. 2019 Apr;34(4):373-379
pubmed: 30238962
World J Surg Oncol. 2018 Nov 12;16(1):221
pubmed: 30419915
Pathol Int. 2008 Dec;58(12):780-6
pubmed: 19067853
HPB (Oxford). 2001;3(1):7-9
pubmed: 18333007
Dis Colon Rectum. 2016 Dec;59(12):1160-1167
pubmed: 27824701
J Gastrointest Surg. 2018 Aug;22(8):1452-1454
pubmed: 29313288
Ann Pathol. 2005 Dec;25(6):511-28
pubmed: 16735976
Int J Surg Pathol. 2015 Aug;23(5):414-8
pubmed: 25838330
Arch Pathol Lab Med. 2016 Oct;140(10):1157-62
pubmed: 27684986
Am Surg. 2019 Feb 1;85(2):e74-e76
pubmed: 30819309
Endocr Pathol. 2009 Winter;20(4):235-42
pubmed: 19707890
Cancers (Basel). 2012 Jan 16;4(1):11-30
pubmed: 24213223
J Gastrointest Cancer. 2019 Jun;50(2):298-303
pubmed: 29435905
Int J Surg Case Rep. 2013;4(5):504-7
pubmed: 23562903
Pathol Int. 2011 Oct;61(10):608-14
pubmed: 21951672
Indian J Pathol Microbiol. 2015 Oct-Dec;58(4):543-5
pubmed: 26549089
Diagn Pathol. 2012 Nov 27;7:163
pubmed: 23186166
Pathol Res Pract. 2010 Jun 15;206(6):397-400
pubmed: 19945229
J Oncol. 2015;2015:967472
pubmed: 26421012
Postgrad Med J. 2009 Apr;85(1002):213-8
pubmed: 19417172
Neuroendocrinology. 2017;105(4):412-425
pubmed: 28803232
Virchows Arch. 2012 Mar;460(3):281-9
pubmed: 22358181
J Clin Gastroenterol. 2010 Nov-Dec;44(10):687-95
pubmed: 20375728
J Nippon Med Sch. 2006 Apr;73(2):101-5
pubmed: 16641536